Brokerages expect Jounce Therapeutics Inc (NASDAQ:JNCE) to report $20.15 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Jounce Therapeutics’ earnings, with the lowest sales estimate coming in at $20 million and the highest estimate coming in at $20.29 million. The business is scheduled to issue its next quarterly earnings report on Tuesday, August 8th.

On average, analysts expect that Jounce Therapeutics will report full year sales of $20.15 million for the current fiscal year, with estimates ranging from $80 million to $81.16 million. For the next financial year, analysts anticipate that the business will post sales of $130.05 million per share, with estimates ranging from $81.16 million to $206 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Tuesday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.07. The company had revenue of $20.30 million for the quarter, compared to analysts’ expectations of $19.71 million. The business’s revenue was up 202900.0% compared to the same quarter last year.

A number of brokerages have weighed in on JNCE. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Wednesday, April 26th. Cowen and Company reissued a “buy” rating on shares of Jounce Therapeutics in a research report on Thursday, April 20th. JPMorgan Chase & Co. began coverage on Jounce Therapeutics in a research report on Tuesday, February 21st. They issued an “overweight” rating and a $28.00 target price for the company. Robert W. Baird began coverage on Jounce Therapeutics in a research report on Tuesday, February 21st. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Wells Fargo & Co began coverage on Jounce Therapeutics in a research report on Tuesday, February 21st. They issued an “outperform” rating for the company. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $28.67.

Jounce Therapeutics (NASDAQ:JNCE) traded down 6.33% during mid-day trading on Friday, reaching $21.90. 143,338 shares of the company were exchanged. Jounce Therapeutics has a one year low of $16.33 and a one year high of $29.29. The stock has a 50-day moving average price of $24.27 and a 200 day moving average price of $22.54. The company’s market capitalization is $703.73 million.

ILLEGAL ACTIVITY WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/05/19/20-15-million-in-sales-expected-for-jounce-therapeutics-inc-jnce-this-quarter.html.

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in Jounce Therapeutics during the first quarter valued at approximately $82,387,000. Wellington Management Group LLP acquired a new stake in Jounce Therapeutics during the first quarter valued at approximately $34,814,000. Redmile Group LLC acquired a new stake in Jounce Therapeutics during the first quarter valued at approximately $22,523,000. Pharmstandard International S.A. acquired a new stake in Jounce Therapeutics during the first quarter valued at approximately $14,559,000. Finally, Omega Fund Management LLC acquired a new stake in Jounce Therapeutics during the first quarter valued at approximately $12,747,000.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

5 Day Chart for NASDAQ:JNCE

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.